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Acute lung exposure to low oxygen results in pulmonary vasoconstriction and redistribution of blood
flow. We used human microvascular endothelial cells from lung (HMVEC-L) to study the acute response
to oxygen stress. We observed that hypoxia and erythropoietin (EPO) increased erythropoietin receptor
(EPOR) gene expression and protein level in HMVEC-L. In addition, EPO dose- and time-dependently stim-
ulated nitric oxide (NO) production. This NO stimulation was evident despite hypoxia induced reduction
of endothelial NO synthase (eNOS) gene expression. Western blot of phospho-eNOS (serine1177) and
eNOS and was significantly induced by hypoxia but not after EPO treatment. However, iNOS increased
at hypoxia and with EPO stimulation compared to normal oxygen tension. In accordance with our previ-
ous results of NO induction by EPO at low oxygen tension in human umbilical vein endothelial cells and
bone marrow endothelial cells, these results provide further evidence in HMVEC-L for EPO regulation of
NO production to modify the effects of hypoxia and cause compensatory vasoconstriction.
 2011 Elsevier Ltd. All rights reserved.1. Introduction
Erythropoietin (EPO) is a hypoxia-inducible cytokine required
for production of mature erythrocytes. EPO acts by binding to
and inducing expression of the erythropoietin receptor (EPOR). Be-
yond erythropoiesis, EPO and EPOR elicit response in numerous tis-
sues, particularly in endothelial cells [1,2]. The ability for EPO to
stimulate cell proliferation and chemotaxis in endothelial cells
was first demonstrated in vitro and then in vivo in the chick cho-
rioallantoic membrane and mouse uterine endometrium [3,4].
The pleiotrophic nature of EPO proliferative and survival response
is observed in a variety of non-hematopoietic cells including tumor
cells [5,6]. Moreover, EPO in combination with low oxygen tension
can increase the endothelial capacity to produce nitric oxide (NO)
by induction of both EPOR and endothelial nitric oxide synthase
(eNOS) [7]. EPO activation of NO production in murine erythro-
cytes has also been reported [8]. EPO stimulated production of
NO may compensate for the enhanced NO scavenging in the pres-
ence of cell-free hemoglobin followed by haptoglobin binding toll rights reserved.
ll Biology Branch, National
iseases, Building 10, Room
92-1822, USA. Tel.: +1 301
chi).facilitate clearance, especially with reduced oxygen availability
[9,10]. Additionally, EPO induced neovascularisation through
endothelial progenitor cells recruitment from the bone marrow
associated with coronary heart disease and possibly acting in con-
junction with stimulated VEGF production by cardiomyocytes
[11,12]. Several in vivo studies demonstrated an EPO protective ef-
fect to endothelial cells in diverse models of vascular disease
[13,14].
Endothelial cells exhibited specific responses in adaptation to
low oxygen tension in lung [15]. Acute exposure to hypoxia re-
sulted in vasoconstriction of pulmonary arteries, increased pul-
monary arterial pressure and redistribution of blood flow from
basal to the apical level of lung. In chronic hypoxic lung disease
dysfunction of mechanisms regulating vascular tone and remodel-
ing of the pulmonary vasculature contribute to the development of
sustained pulmonary hypertension [16]. Chronic hypoxia stimu-
lated polycytemia results in increased blood viscosity and pulmon-
ary hypertension.
NO has a central role in modulation of pulmonary vascular tone.
Three isoforms of the enzyme responsible for the NO production
are endothelial, inducible (iNOS) and neuronal (nNOS) [17,18].
All three isoforms are increased in chronic hypoxic pulmonary
hypertension [19]. eNOS and nNOS are constitutively expressed
NOS isoforms and require calcium for activation, while iNOS is
calcium independent but inducible by cytokines. In the normal
130 B.B. Beleslin-Čokić et al. / Cytokine 54 (2011) 129–135murine pulmonary circulation nNOS does not modulate tone,
whereas eNOS-derived NO is the principle mediator of endothe-
lium-dependent vasodilation in the pulmonary circulation, and
both eNOS and iNOS play a role in modulating basal tone chroni-
cally [20]. eNOS is the principal isoform expressed in the normal
pulmonary vasculature [21].
To clarify the response of lung endothelial cells to EPO stimula-
tion, we examined the levels of EPOR and eNOS/iNOS expression in
cultured endothelial cells at normoxia and low oxygen tension. We
found that EPO increased expression of EPOR, particularly at low
oxygen tension. EPO had little effect on NO production at nor-
moxia. At hypoxia, concomitant with the increase in EPOR expres-
sion, EPO increased production of NO up to 4 h. This EPO induction
of NO was NOS dependent and evident despite hypoxia induced
down regulation of eNOS mRNA and protein expression. The activ-
ity of eNOS is regulated primarily by post-translational mecha-
nisms including phosphorylation at multiple sites, but one of the
most studied sites is the activation of serine 1177. However, ratio
for phosphorylated eNOS at serine 1177 and eNOS, showed in-
creased in there activity at low oxygen but not after EPO stimula-
tion. In contrast, Western blotting showed that iNOS increased at
low oxygen tension and even further when combined with EPO
treatment. These data suggest that the low level of NO induced
at low oxygen tension by EPO stimulation in lung endothelial cells
is NOS dependent and concomitant with increase in the low level
of iNOS protein expression but decrease in eNOS activity.2. Materials and methods
2.1. HMVEC-L cell culture
Human microvascular endothelial cells from lung (HMVEC-L;
Clonetics Endothelial Cell System, Lonza, Walkersville, MD) were
cultured in endothelial basal media (EGM-2MV) containing 5%
FBS and cytokines under 5% CO2 with balanced 95% room air. Be-
fore exposure to 2% oxygen, cells were washed in HEPES buffer
(N-2-hydroxyethylpiperazine-N0-2-ethanesulfonic acid) and plated
in EBM-2 containing 1% FBS and cytokines. Incubator (Forma Scien-
tific, Marietta, OH) with low oxygen control capability was used to
generate reduced oxygen tension.
2.2. Real-time quantitative RT-PCR
At third passage, HMVEC-L were plated at cell density of 3000
cells in 35 mm culture dishes at normal and reduced oxygen ten-
sions with and without EPO (5 U/ml). After two days, the cells were
harvested, RNA was isolated using STAT 60 (Tel-TEST, Friends-
wood, TX) and treated with RNase-Free DNase (Promega, Madison,
WT). Total RNA (1 lg) of each sample was used for cDNA synthesis
using murine leukemia virus (MuLV) reverse transcriptase (RT) and
oligo d(T)16 (Applied Biosystems, Foster City, CA). Quantitative
real-time RT-PCR analysis was performed using the ABI PRISM
7700 Detection System (Applied Biosystems). The conditions and
Taqman oligonucleotide probes (Applied Biosystems) were used
as previously described [7]. Beta-actin was used as an internal con-
trol for the total amount of RNA analyzed.
2.3. Protein analysis
HMVEC-L cells were plated in EBM-2 media with and without
5 U/ml EPO. After 48 h, cells were washed with HEPES buffer, trea-
ted with lysis buffer and detached from the plate. The cell lysate
was centrifuged for 10 min and the supernatant was transferred
to a new tube. For EPOR analysis, 1 mg of protein was incubated
with EPOR antibody (Santa Cruz Biotechnology, Santa Cruz, CA)overnight. The complex was captured with protein A-Agarose (San-
ta Cruz Biotechnology) for 2 h at 4 C, washed two times and incu-
bated at 70 C for 10 min. The proteins were separated by sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS–PAGE)
and transferred to a nitrocellulose membrane. The membrane
was blocked with 5% milk with 0.1% Tween 20 for 1 h at room
air and probed with primary antibody specific for EPOR antibody
(Santa Cruz Biotechnology), 1:1000 at 4 C overnight. Hyperfilm
was developed to visualize the secondary antibody by enhanced
chemiluminescence (ECL; Amersham Pharmacia Biotech, Piscata-
way, NJ). For Western blotting using anti-eNOS (BD Transduction
Laboratories, San Jose, CA), anti-phospho-eNOS (Ser1177), and
anti-iNOS (Cell Signaling Technology, Inc.) antibodies, HMVEC-L
were treated with EPO (5 U/ml) for 48 h. Cells were washed with
HEPES, treated with lysis buffer and scraped from the plate. The
proteins were separated by SDS–PAGE and transferred to a nitro-
cellulose membrane, blocked with primary antibody overnight at
4 C and visualized by chemiluminescence. The membrane was
stripped for 1 h, washed, blocked and incubated with the b-actin
antibody (Sigma, St. Louis, MO) overnight at 4 C and then visual-
ized. The Java image-processing program inspired by NIH image
was used for quantitative analysis.
2.4. Ozone-based chemiluminescent determination of nitrite/nitrate in
supernatant of cell culture
For only nitrite measurement, confluent HMVEC-L in 6-well
plates were washed once with HEPES buffer (BioWhittaker Inc.)
and EBM-2 was added (total volume 2 ml). HMVEC-L were pre-
treated for 30 min with 1 mM L-NG-Nitro-arginine-methyl ester
(L-NAME, Alexis Biochemicals). The cells were exposed to EPO (1,
5, 10 U/ml) in the presence of L-arginine (Sigma–Aldrich, St. Louis,
MO). After incubation period, the supernatants of treated cells
were injected in reductants in line with the Sievers Model 280
NO analyser (Sievers, Boulder, CO). NO was measured by nitrite
reduction in acidified KI: 7 ml of glacial acetic acid, 2 ml of distilled
water, 50 mg of KI, a crystal of iodine was added to yield a concen-
tration of 6 to 20 mmol/l (Sigma–Aldrich). Helium was bubbled
through the reaction mixture. For combined nitrite/nitrate mea-
surement, confluent HMVEC-L in small flasks were washed once
with HEPES buffer and EBM-2 was added (total volume 5 ml). After
EPO treatment (5 U/ml) and 4 h of incubation, nitrite levels were
measured as previously described, whereas nitrate levels were
measured using vanadium (III) chloride in hydrochloric acid at
90 C with the Sievers Model 280 NO analyser.
2.5. Statistical analysis
The one way analysis of variance (ANOVA) and Dunnett’s post
tests were applied using Prism 4 software (GraphPad Software
Inc., San Diego, CA).3. Results
3.1. EPOR expression in HMVEC-L
Our previous results on EPO activity in endothelial cells indi-
cated that the optimal concentration of EPO stimulation of EPOR
expression is 5 U/ml [7]. To investigate EPOR expression in
HMVEC-L, cells were exposed to normal (21% O2) and low (2%
O2) oxygen tension for 48 h. We observed that EPO (5 U/ml) in-
duced EPOR mRNA in lung endothelial cells at normal oxygen ten-
sion (Fig. 1A). The increase of EPOR mRNA was also observed at 2%
O2 (P < 0.01) and adding EPO to the culture media further doubled
EPOR expression (Fig. 1A). Western blotting showed that EPO
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protein more than 3-fold compared to cultures at 21% O2 with and
without EPO (Fig. 1B). Therefore, while EPO had no effect on EPOR
protein level at normoxia, quantification of the EPOR bands from
Western blotting (Fig. 1C) showed significant EPOR induction after
EPO stimulation at low oxygen tension (P < 0.01). EpoR appeared to
increase with hypoxia, but this increase is not significant. These re-
sults demonstrated stimulative effects of EPO and hypoxia on total
EPOR levels in HMVEC-L.3.2. NO production in HMVEC-L
We previously found that EPO stimulated NO production in se-
lected endothelial cells through eNOS activation that was reflected
in increased eNOS expression and phosphorylation [7]. HMVEC-L
were treated with different concentrations of EPO (1, 5 and 10 U/
ml) at 21% and 2% oxygen. The NO production after EPO stimula-
tion was measured at 30 min (Fig. 2), 1 h (Fig. 3) and 4 h (Fig. 4).
EPO did not induce statistically significant changes in NO produc-Fig. 1. Induction of EPOR by hypoxia and EPO in HMVEC-L. (A) EPOR expression
was determined by quantitative real-time PCR at 21% and 2% O2, with (black bars)
and without (open bars) EPO (5 U/ml) treatment. EPOR gene expression was
induced with EPO after 48 h at 21% and 2% O2. Results were normalized to b-actin
expression. Values are means ± SEM (n = 3). ⁄⁄P < 0.01 compared to nontreated cells.
(B) EPOR protein induction by EPO in normoxia vs. hypoxia as measured by Western
blotting. (C) Quantification of EPOR Western blotting showed significant induction
up to 3-fold at 2% O2 after EPO treatment. Open bars demonstrate 21% and 2% of
oxygen and black bars cells treated with EPO. Values are means ± SEM (n = 3).
⁄⁄P < 0.01 compared to samples under normoxia.tion at 21% oxygen at all time points (Figs. 2B, 3B and 4). L-NAME
treatment in combination with EPO decreased NO production com-
pared with EPO alone.
HMVEC-L cultured at 2% oxygen exhibited a greater response to
EPO, consistent with the up regulation of EPOR expression (Fig. 1).
The optimum for NO production was observed with 5 U/ml of EPO
at 30 min, 1 h and 4 h (Figs. 2A, 3A and 4). NO induction increased
with time and appeared greatest after 4 h. Addition of NOS inhibi-
tor L-NAME, decreased the EPO induction of NO at all three time
points at 2% oxygen.
3.3. Nitrite and nitrate production in HMVEC-L
Endothelial NO synthesis is important in controlling vascular
tone and blood pressure [22]. Under normal physiological condi-
tions, nitrite, along with NO and nitrate, is part of a complex bio-
logical cycle in mammals [23]. NO itself is short-lived, as it is
rapidly oxidized to nitrite in aqueous solutions, and directly oxi-
dized to nitrate in the presence of superoxide or oxyhemoglobin
[24]. Inorganic nitrate synthesis results from NO oxidation and
may be an important storage form of reactive nitrogen oxides,
which can be reduced back to nitrite and then NO under certain
physiological and pathological conditions [23]. In HMVEC-L re-
leased NO was monitored using nitrate and nitrite levels as an in-
dex of NO production.
After 4 h of HMVEC-L stimulation by EPO (5 U/ml) nitrite levels
were significantly induced at low oxygen tension (Fig. 5A). There
was about the same production of nitrite in HMVEC-L cultured at
21% and 2% of oxygen. However, overall nitrate production in cells
was as expected higher in comparison to nitrite levels and signifi-
cantly stimulated by hypoxya itself (Fig. 5B). EPO remarkably stim-
ulated nitrate production both at normal and low oxygen tension
(Fig. 5B), suggesting that nitrite rapidly converts to nitrate.Fig. 2. Effects of EPO on nitrite production in HMVEC-L at hypoxic and normoxic
condition at 30 min. Effects of 1, 5 and 10 U/ml of EPO stimulation on NO2
production after 30 min were determined at 2% O2 (A) and 21% oxygen (B). The
effect of EPO treatment at 5 U/ml on NO2 production is shown as a shaded bar. NO
production was measured as released nitrite in the supernatant per 105 cells. 1 mM
L-NAME was added in the presence of 5 U/ml of EPO. Values are means ± SEM
(n = 3). ⁄P < 0.05 compared to control and L-NAME treatment.
Fig. 3. Effects of EPO on nitrite production in HMVEC-L at hypoxic and normoxic
condition at 1 h. Cells were treated with 1, 5 and 10 U/ml of EPO on NO2
production after 1 h were determined at 2% (A) and 21% oxygen (B). Shaded bar
with 5 U/ml of EPO represents the optimum effect on NO2 production. NO
production was measured as released nitrite in the supernatant per 105 cells. 1 mM
L-NAME suppressed NO induction stimulated by 5 U/ml of EPO. Values are
means ± SEM (n = 3). ⁄P < 0.05 compared to control and L-NAME treatment.
Fig. 4. Effects of EPO on nitrite production in HMVEC-L at hypoxic and normoxic
condition at 4 h. Cells were treated with 1, 5 and 10 U/ml of EPO on NO2
production after 4 h were determined at 2% (A) and 21% oxygen (B). Shaded bar
with 5 U/ml of EPO represents the optimum effect on NO2 production. NO
production was measured as released nitrite in the supernatant per 105 cells. One
millimolar L-NAME suppressed NO induction stimulated by 5 U/ml of EPO. Values
are means ± SEM (n = 3). ⁄P < 0.05 compared to control and L-NAME treatment.
Fig. 5. Production of nitrite and nitrate in HMVEC-L. Cells were cultured at 21% and
2% oxygen with (black bars) and without (open bars) 5 U/ml of EPO for 4 h. (A)
Nitrite levels (NO2) showed the induction after EPO stimulation at 2% oxygen. (B)
Nitrate levels (NO3) were induced with EPO at normal and low oxygen tension.
Values are means ± SEM (n = 3). ⁄P < 0.05 compared to at normoxia. ⁄⁄P < 0.01
compared to cells at normoxia.
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The three known isoforms of NOS were identified in the lung,
two constitutive NOS isoforms are neuronal (nNOS) and endothe-
lial (eNOS), they are regulated by calcium and calmodulin ions
and release NO in small (nanomolar) quantities. However, this
quite limited NO production by constitutive NOS are sufficient to
keep the extremely vasodilated baseline systemic vascular tone
stable, inhibit the interaction of leukocytes with the endothelium,
inhibit platelet aggregation and control cell proliferation [25]. The
third isoform of NOS is inducible iNOS isoform, independent of cal-
cium and calmodulin ions, which promotes the release of greater
(micromolar) amounts of NO. It is known that iNOS isoform can
be induced by inflammatory stimuli [26].
Expression of eNOS and iNOS were examined in HMVEC-L. Cells
were cultured with and without EPO for 48 h and we found that
expression of eNOS mRNA was significantly decreased at 2% oxy-
gen (P < 0.01, Fig. 6A). This change in eNOS expression is analogous
to the 2- to 4-fold decrease we previously observed in primary
endothelial cells from human umbilical vein (HUVEC) and artery
(HUAEC) when cells were cultured at reduced oxygen tension [7].
Adding EPO (5 U/ml) did not affect expression of eNOS mRNA in
HMVEC-L (data not shown). Western blotting of eNOS showed that
expression was reduced up to 2-fold at 2% O2. Moreover, antibody
specific for eNOS phosphorylated at serine 1177 followed the de-
crease in protein and mRNA expression of eNOS (Fig. 6B and C).
However, when we examined the ratio phospho eNOS to eNOS
we found statistically significant changes in expression but only
at low oxygen (Fig. 6D). The reduction of eNOS expression at the
mRNA and protein levels by hypoxia, not significantly reversed
by EPO treatment, may account for the relatively low EPO
induction of NO production in HMVEC-L in comparison to HUVEC
or HUAEC where NO production was an order of magnitude greater
following EPO treatment [7]. Interestingly, iNOS protein was
Fig. 6. eNOS, p-eNOS, iNOS expression in HMVEC-L. (A) eNOS expression was
determined by quantitative real-time RT-PCR at 21% and 2% O2. There was a
significant decrease of eNOS expression at 2% O2. Results were normalized to b-
actin expression. Values are means ± SEM (n = 3). ⁄⁄P < 0.01 compared to cells at
normoxia. (B) Western blotting analysis confirmed the decreased expression of
eNOS and p-eNOS at 2% O2 that persisted with EPO stimulation. iNOS expression
was induced at 2% oxygen and even more with 5 U/ml of EPO. (C) Quantification of
eNOS, p-eNOS and iNOS in relation to b-actin. (D) Quantification of p-eNOS/eNOS
ratio from Western blotting. ⁄P < 0.05 compared to at normoxia. ⁄⁄P < 0.01
compared to cells at normoxia.
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ulation. These data suggest that small amounts of NO produced in
HMVEC-L under low oxygen tension could be accompanied with
induction of iNOS protein with hypoxia and more with EPO, but
not eNOS in lung microvascular cells.4. Discussion
Hypoxia increased EPOR mRNA and protein levels in HMVEC-L
that are further induced by EPO particularly at low oxygen ten-sion. Induction of EPOR mRNA by EPO is regulated in part through
activation of GATA transcription factors as observed in erythroid,
myoblast and neuronal cells [27–29]. In addition, EPOR reporter
gene assays show a direct response of EPOR promoter activity
to reduced oxygen tension as well as increased NO production
in neuronal cells [30], providing insight on the induction of EPOR
expression by EPO and hypoxia. Hypoxia reduced eNOS mRNA
and protein levels at 2% O2. This change in phospho-eNOS/eNOS
is small and reduction in eNOS protein is considerably larger so
that is very likely that there is an overall reduction in eNOS activ-
ity. EPO stimulated NO production in HMVEC-L at low oxygen
tension, although the level of NO production was markedly lower
than the level of EPO-induced NO in HUVEC reflecting the overall
reduction of eNOS by hypoxia [7]. EPO stimulated nitrite and
even more nitrate production at normal and low oxygen tension,
suggesting that nitrite rapidly converts to nitrate. In contrast to
eNOS, iNOS was induced with low oxygen and EPO stimulation.
Compared with previous reports of EPO stimulation of endothelial
NO production, these data indicate variation in endothelial re-
sponse in EPO-induced NO at hypoxia consistent with endothelial
cell diversity in tissue specific response.
The pulmonary endothelium is important for the maintenance
of the blood flow in the pulmonary vasculature. When the lungs
are exposed to low oxygen, pulmonary arteries exhibit vasocon-
striction and redistribution of blood flow [15]. Chronic hypoxia
decreases the luminal diameter of the small pulmonary arteries
and increases vascular resistance, contributing to the develop-
ment of hypertension [31]. Also, chronic hypoxia stimulates pro-
duction of erythrocytes and polycythemia, resulting in increased
blood viscosity and can contribute to pulmonary hypertension
[32]. Beyond excessive erythrocytosis and/or polycythemia, a
variety of other factors have been implicated in the mechanisms
of pulmonary hypertension such as hypoxia, vascular remodeling
and NO. In transgenic mice with constitutively overexpressed hu-
man EPO gene, pulmonary artery pressure was increased in vivo
but was reduced in blood-free perfused lungs [33]. These mice
have polycythemia but normal blood pressure, heart rate and car-
diac output and in pulmonary vasculature elevated prostacyclin
production, eNOS expression and reduced vascular smooth mus-
cle thickness. Since these mice have elevated pulmonary hyper-
tension in vivo but not in vitro, it suggests that their
pulmonary hypertension is due to the increased blood viscosity.
With respect to tissue hypoxia, our results showed that eNOS
expression was decreased when HMVEC-L were exposed to 2%
O2 for 48 h, suggesting that the long incubation and low oxygen
tension dramatically changed eNOS expression locally in the pul-
monary tissue. Stimulation with 5 U/ml of EPO did not reverse the
decreased eNOS expression, in contrast to EPO induction of eNOS
in HUVEC [7]. The iNOS isoform can be induced by inflammatory
stimuli [26]. Recent evidence has revealed that NO production is
increased in lung diseases accompanied by intense inflammation,
such as acute respiratory distress syndrome (ARDS) and that NO
derived from iNOS might aggravate such diseases [34]. It has been
observed that patients with ARDS present elevated lung concen-
trations of NO metabolites (nitrite and nitrate) and 3-nitrotyro-
sine [35]. Because of this findings it is proposed that selective
iNOS inhibition can have beneficial effects in the treatment of
lung diseases accompanied by inflammation and pulmonary arte-
rial hypertension, but not yet clinically validated. In case of
HMVEC-L the level of iNOS was low compare to eNOS. But after
48 h iNOS protein increased as oxygen decreased to 2% and fur-
ther more after EPO stimulation. Of note, the amount of iNOS pro-
tein is only one of several factors that regulate iNOS generated
NO production [36]. However, these data suggest that acute expo-
sure of HMVEC-L to low oxygen may produce NO via a mecha-
nism independent of eNOS activation, but is insufficient to
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vasoconstriction.
The differential response of various endothelial beds to EPO
may explain in part the role of EPO in modulating endothelial re-
sponse related to the pulmonary vasculature. Several reports sug-
gest that EPO may serves as a cytokine that elicits mobilization
of endothelial progenitor cells promoting the repair process of
the injured pulmonary endothelium [14]. EPOR-null mutant mice
expressing EPOR exclusively in the erythroid lineage (EPOR/ res-
cued mice) showed accelerated pulmonary hypertension and pul-
monary vascular remodeling, illustrating the importance of EPO
and EPOR for pulmonary endothelial function [14]. Our data sug-
gest that primary endothelial cells from lung after stimulation with
EPO at low oxygen tension induced EPOR and increased NO pro-
duction, but did not significantly affect the inhibition of eNOS
expression, while iNOS began to induce within 48 h. In EPOR/
rescued mice, when bone-marrow derived endothelial progenitor
cells were intravenously infused, incorporation of endothelial cells
was significantly impaired comparing to wild type animals, again
suggesting the significance EPO and EPOR in endothelial cells. In
wild-type mice after three weeks exposure to 10% oxygen, endo-
thelial cells were incorporated into the pulmonary endothelium
and EPOR and eNOS were induced [14]. On the other hand, NO is
also a reactive radical capable of tissue injury either directly or
after reacting with other radicals. There is evidence that when rats
are exposed to 10% oxygen, NO production is increased during the
first days of hypoxia, mostly by the iNOS isoform [36]. It was sug-
gested that transient iNOS induction in the pulmonary vascular
wall at the beginning of chronic hypoxia participates later in the
pathogenesis of pulmonary hypertension [37]. Our data also sug-
gest that after 48 h of exposure to 2% oxygen, there was an increase
in iNOS protein that increased further with EPO treatment.
Taken together, our data suggest that the increase of plasma
EPO level in response to oxygen stress results in upregulated EPOR
in lung endothelial cells accompanied by the NOS dependent small
induction of NO that may be insufficient to counteract hypoxic
vasoconstriction.Acknowledgments
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